Full Year 2019 Mesoblast Ltd Earnings Call Transcript
Good morning, good afternoon, everybody, and thank you for joining us at the operational and financial results for the fiscal year ended June 30, 2019. With me is our Chief Financial Officer, Josh Muntner.
If we could go straight to Slide 4, please. This is a snapshot of our corporate history. We have over a decade of scientific, manufacturing, clinical development and corporate development experience, which target at bringing to market our allogeneic, off-the-shelf cellular medicines for a raft of very severe inflammatory diseases.
Next slide. Our company is underpinned by 3 major factors: we have an innovative technology platform, we have a late-stage pipeline and we have products already commercialized and underway. Our technology platform targets some of the most severe disease states that are currently refractory to conventional therapies. We have well-characterized multimodal mechanism of action which we understand well and position ourselves to tackle these diseases
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
